Brokerage firm Stifel Nicolaus Downgrades its rating on Innocoll AG(INNL). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at Stifel Nicolaus was issued on Mar 17, 2017 in a research report to their Investors and Clients.
In a different note, On Dec 30, 2016, Janney Capital said it Downgrades its rating on Innocoll AG. In the research note, the firm Lowers the price-target to $2 per share. The shares have been rated ‘Neutral’ by the firm.
Innocoll AG (INNL) made into the market gainers list on Wednesdays trading session with the shares advancing 13.33% or 0.14 points. Due to strong positive momentum, the stock ended at $1.19, which is also near the day’s high of $1.4. The stock began the session at $1.07 and the volume stood at 42,84,825 shares. The 52-week high of the shares is $12.94 and the 52 week low is $0.53. The company has a current market capitalization of $469 M and it has 39,40,16,410 shares in outstanding.
Innocoll AG(INNL) last announced its earnings results on Mar 16, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $590.000K. Analysts had an estimated revenue of $1.130M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.4.
Innocoll AG formerly Innocoll GmbH is a global commercial-stage specialty pharmaceutical company with late-stage development programs. The Company’s lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections or DFIs. The Company has initiated Phase III efficacy trials for Cogenzia in both the United States and Europe. The Company has initiated a pivotal pharmacokinetic study for XaraColl. CollaGUARD which prevents post-surgical adhesions is approved in 48 countries in Europe Asia the Middle East and Latin America. The Company products consist of CollatampG surgical implant RegenePro Durieva and Septocoll in a range of topical and implantable forms including sponges films membranes and gels compatible with a range of therapeutics including hydrophobic and hydrophilic active ingredients and small molecules and biologics. It also offers CollaCare Suite for wound care.